Physician profile
Robert Babkowski
NPI 1124006341
$76,233.11
in general payments reported to CMS, 2019-2025
12 companies · $48.15 in 2025
The $48.15 reported for 2025 was less than what a typical Anatomic Pathology & Clinical Pathology provider received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $17K · 2021: $8,479 · 2022: $700 · 2023: $9,092 · 2024: $1,645 · 2025: $48.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,950 · Consulting Fee: $1,545 · Travel and Lodging: $1,124 · Food and Beverage: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,950.00 |
| Consulting Fee | $1,545.00 |
| Travel and Lodging | $1,123.88 |
| Food and Beverage | $166.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $63,924.71 | 2019-2024 | |
| Abbott Laboratories | $8,829.43 | 2021-2025 | Aliniq, Alinity |
| Amgen INC. | $2,332.00 | 2021 | |
| Illumina, INC. | $375.00 | 2023 | Oncology Testing/Genetic Disease Testing |
| Cepheid | $375.00 | 2023 | |
| Foundation Medicine, INC. | $140.11 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.00 | 2019 | |
| Hologic Sales and Service, LLC | $76.21 | 2019-2024 | Trident Specimen Radiography System |
| Siemens Medical Solutions USA, INC. | $36.56 | 2024 | Atellica Ch 930 Analyzer |
| Beckman Coulter, INC. | $32.80 | 2025 | Dxa 5000 |
| Roche Diagnostics Corporation | $18.52 | 2023 | Cintec Plus Cytology |
| Merck Sharp & Dohme LLC | $14.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Babkowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.